Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial (NCT06980025) | Clinical Trial Compass
RecruitingPhase 3
Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial
United States1,800 participantsStarted 2025-07-01
Plain-language summary
This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.
Who can participate
Age range14 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 14 years or older
* Singleton gestation. Twin gestation reduced to a singleton, either spontaneously or therapeutically, is not eligible unless the reduction occurred before 13 weeks 6 days project gestational age. Higher-order multifetal gestations reduced to singletons are not eligible.
* Gestational age at randomization between 10 weeks 0 days and 15 weeks 6 days based on clinical information and evaluation of the earliest ultrasound.
* Prior preterm birth between 20 weeks 0 days and 34 weeks 6 days with one of the following in the proximal birth reaching 20 weeks or greater:
* Spontaneous preterm birth is defined as spontaneous preterm labor or premature rupture of membranes
* Ischemic placental disease is defined as preeclampsia, small for gestational age, fetal growth restriction, or placental abruption, as defined clinically.
* Stillbirth excluding those with known genetic disorders or major congenital anomalies.
Exclusion Criteria:
* Known allergy or hypersensitivity to aspirin or any medical condition where aspirin is contraindicated (e.g., history of peptic ulcer disease, nasal polyps, NSAID-induced asthma, history of gastrointestinal bleeding, known G6PD deficiency, severe hepatic dysfunction, bleeding disorders, and consumption of 3 or more alcoholic drinks per day)
* Taking other anticoagulants such as Heparin or Low-Molecular weight Heparin
* Thrombocytopenia defined as a platelet count defined as a platelet count \<100,000 microl…
What they're measuring
1
Rate of recurrent preterm delivery or fetal death prior to 35 weeks 0 days gestation
Timeframe: Between randomization and 35 weeks, 0 days gestation (a period of up to 25 weeks)
Trial details
NCT IDNCT06980025
SponsorThe George Washington University Biostatistics Center